星空体育官方入口网站网址大全-登录入口官网

#大B细胞淋巴瘤#

2篇内容 | 1481人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2216459, encodeId=20e7221645980, content=<a href='/topic/show?id=247743555b6' target=_blank style='color:#2F92EE;'>#大B细胞淋巴瘤#</a> <a href='/topic/show?id=0d3240e64e' target=_blank style='color:#2F92EE;'>#CAR-T细胞治疗#</a> <a href='/topic/show?id=c0ad429356' target=_blank style='color:#2F92EE;'>#CD22#</a>, objectTitle=柳叶刀发表CD22 CAR-T治疗CAR19失败的LBCL的I期研究，新的希望即将来临？, objectType=article, longId=835565, objectId=bd9683556534, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240719/1721377067764_92910.png, objectUrl=/article/show_article.do?id=bd9683556534, replyNumber=0, likeNumber=8, createdTime=2024-07-23, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=bd9683556534, moduleTitle=柳叶刀发表CD22 CAR-T治疗CAR19失败的LBCL的I期研究，新的希望即将来临？, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=bd9683556534)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2214233, encodeId=0dd222142333f, content=<a href='/topic/show?id=31978e07508' target=_blank style='color:#2F92EE;'>#苯达莫司汀#</a> <a href='/topic/show?id=247743555b6' target=_blank style='color:#2F92EE;'>#大B细胞淋巴瘤#</a> <a href='/topic/show?id=978a113610c8' target=_blank style='color:#2F92EE;'>#R/R LBCL#</a>, objectTitle=【Hemasphere】苯达莫司汀作为R/R LBCL CAR-T桥接治疗安全有效, objectType=article, longId=833752, objectId=b9a0833e52e2, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240710/1720579036530_1608702.png, objectUrl=/article/show_article.do?id=b9a0833e52e2, replyNumber=0, likeNumber=26, createdTime=2024-07-10, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=b9a0833e52e2, moduleTitle=【Hemasphere】苯达莫司汀作为R/R LBCL CAR-T桥接治疗安全有效, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=b9a0833e52e2)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2212777, encodeId=4ce12212e77ff, content=<a href='/topic/show?id=247743555b6' target=_blank style='color:#2F92EE;'>#大B细胞淋巴瘤#</a> <a href='/topic/show?id=141d40627a' target=_blank style='color:#2F92EE;'>#CAR-T#</a> <a href='/topic/show?id=a80f10e3046' target=_blank style='color:#2F92EE;'>#LBCL#</a>, objectTitle=CAR-T治疗后进展LBCL患者的后续治疗及结局, objectType=article, longId=827854, objectId=a1cf82e85422, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240628/1719538044546_5579292.jpg, objectUrl=/article/show_article.do?id=a1cf82e85422, replyNumber=0, likeNumber=28, createdTime=2024-07-02, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=a1cf82e85422, moduleTitle=CAR-T治疗后进展LBCL患者的后续治疗及结局, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=a1cf82e85422)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2211800, encodeId=9d20221180010, content=<a href='/topic/show?id=247743555b6' target=_blank style='color:#2F92EE;'>#大B细胞淋巴瘤#</a> <a href='/topic/show?id=8f6c254e71b' target=_blank style='color:#2F92EE;'>#代谢肿瘤体积#</a>, objectTitle=【Blood】ZUMA-7研究探索性分析，代谢肿瘤体积可预测结局, objectType=article, longId=831718, objectId=fbc6831e1860, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240625/1719325149652_5579292.png, objectUrl=/article/show_article.do?id=fbc6831e1860, replyNumber=0, likeNumber=26, createdTime=2024-06-26, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=fbc6831e1860, moduleTitle=【Blood】ZUMA-7研究探索性分析，代谢肿瘤体积可预测结局, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=fbc6831e1860)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2210091, encodeId=ad4f2210091d9, content=<a href='/topic/show?id=247743555b6' target=_blank style='color:#2F92EE;'>#大B细胞淋巴瘤#</a> <a href='/topic/show?id=141d40627a' target=_blank style='color:#2F92EE;'>#CAR-T#</a>, objectTitle=【AJH】CD19 CAR-T治疗226例高龄RR LBCL患者安全有效, objectType=article, longId=830220, objectId=ff5a830220a4, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240615/1718464643656_92910.jpg, objectUrl=/article/show_article.do?id=ff5a830220a4, replyNumber=0, likeNumber=28, createdTime=2024-06-15, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=ff5a830220a4, moduleTitle=【AJH】CD19 CAR-T治疗226例高龄RR LBCL患者安全有效, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=ff5a830220a4)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2208666, encodeId=9609220866618, content=<a href='/topic/show?id=247743555b6' target=_blank style='color:#2F92EE;'>#大B细胞淋巴瘤#</a> <a href='/topic/show?id=141d40627a' target=_blank style='color:#2F92EE;'>#CAR-T#</a>, objectTitle=【Hemasphere】387例LBCL患者CAR-T治疗进展后的治疗及结局, objectType=article, longId=829004, objectId=8f4482900415, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240606/1717660439509_5579292.jpg, objectUrl=/article/show_article.do?id=8f4482900415, replyNumber=0, likeNumber=0, createdTime=2024-06-06, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=8f4482900415, moduleTitle=【Hemasphere】387例LBCL患者CAR-T治疗进展后的治疗及结局, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=8f4482900415)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2208486, encodeId=2d1422084869e, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a> <a href='/topic/show?id=247743555b6' target=_blank style='color:#2F92EE;'>#大B细胞淋巴瘤#</a> <a href='/topic/show?id=a80f10e3046' target=_blank style='color:#2F92EE;'>#LBCL#</a>, objectTitle=【BJH】axi-cel二线治疗早期复发或原发难治LBCL的真实世界经验, objectType=article, longId=828894, objectId=c4d7828894bf, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240605/1717570813056_5579292.jpg, objectUrl=/article/show_article.do?id=c4d7828894bf, replyNumber=0, likeNumber=33, createdTime=2024-06-05, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=c4d7828894bf, moduleTitle=【BJH】axi-cel二线治疗早期复发或原发难治LBCL的真实世界经验, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=c4d7828894bf)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2207870, encodeId=9fe0220e87032, content=<a href='/topic/show?id=247743555b6' target=_blank style='color:#2F92EE;'>#大B细胞淋巴瘤#</a> <a href='/topic/show?id=68d6115128e1' target=_blank style='color:#2F92EE;'>#格菲妥单抗#</a>, objectTitle=【Blood Adv】格菲妥单抗治疗DLBCL中≥2级CRS的预测模型, objectType=article, longId=828343, objectId=651d82834325, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240601/1717250825584_5579292.jpg, objectUrl=/article/show_article.do?id=651d82834325, replyNumber=0, likeNumber=66, createdTime=2024-06-01, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=651d82834325, moduleTitle=【Blood Adv】格菲妥单抗治疗DLBCL中≥2级CRS的预测模型, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=651d82834325)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2205822, encodeId=6e3122058222d, content=<a href='/topic/show?id=247743555b6' target=_blank style='color:#2F92EE;'>#大B细胞淋巴瘤#</a> <a href='/topic/show?id=141d40627a' target=_blank style='color:#2F92EE;'>#CAR-T#</a> <a href='/topic/show?id=a80f10e3046' target=_blank style='color:#2F92EE;'>#LBCL#</a>, objectTitle=Leukemia：完全缓解的LBCL患者接受CAR-T细胞治疗：一项CIBMTR分析, objectType=article, longId=826858, objectId=973982685879, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240521/1716265568710_5579292.jpg, objectUrl=/article/show_article.do?id=973982685879, replyNumber=0, likeNumber=60, createdTime=2024-05-21, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=973982685879, moduleTitle=Leukemia：完全缓解的LBCL患者接受CAR-T细胞治疗：一项CIBMTR分析, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=973982685879)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2204281, encodeId=03fc2204281dd, content=<a href='/topic/show?id=247743555b6' target=_blank style='color:#2F92EE;'>#大B细胞淋巴瘤#</a> <a href='/topic/show?id=a80f10e3046' target=_blank style='color:#2F92EE;'>#LBCL#</a>, objectTitle=【Blood Adv】前瞻性研究明确定义原发难治性大B细胞淋巴瘤的概念, objectType=article, longId=825529, objectId=45f482552988, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240512/1715509447146_5579292.jpg, objectUrl=/article/show_article.do?id=45f482552988, replyNumber=0, likeNumber=69, createdTime=2024-05-12, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=45f482552988, moduleTitle=【Blood Adv】前瞻性研究明确定义原发难治性大B细胞淋巴瘤的概念, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=45f482552988)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2203887, encodeId=fe31220388e95, content=<a href='/topic/show?id=e58d60299c' target=_blank style='color:#2F92EE;'>#DLBCL#</a> <a href='/topic/show?id=247743555b6' target=_blank style='color:#2F92EE;'>#大B细胞淋巴瘤#</a> <a href='/topic/show?id=b2f61143192e' target=_blank style='color:#2F92EE;'>#免疫豁免#</a>, objectTitle=blood综述：免疫豁免部位的原发性大B细胞淋巴瘤, objectType=article, longId=825049, objectId=b7a8825049cb, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240510/1715318194666_92910.png, objectUrl=/article/show_article.do?id=b7a8825049cb, replyNumber=0, likeNumber=55, createdTime=2024-05-10, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=b7a8825049cb, moduleTitle=blood综述：免疫豁免部位的原发性大B细胞淋巴瘤, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=b7a8825049cb)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2203756, encodeId=06902203e56ca, content=<a href='/topic/show?id=247743555b6' target=_blank style='color:#2F92EE;'>#大B细胞淋巴瘤#</a> <a href='/topic/show?id=8f6c254e71b' target=_blank style='color:#2F92EE;'>#代谢肿瘤体积#</a> <a href='/topic/show?id=a80f10e3046' target=_blank style='color:#2F92EE;'>#LBCL#</a>, objectTitle=【Blood】ZUMA-7研究探索性分析，代谢肿瘤体积影响患者结局, objectType=article, longId=825081, objectId=03a3825081b6, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/medical-staff-meeting-GXNVP9J.jpg, objectUrl=/article/show_article.do?id=03a3825081b6, replyNumber=0, likeNumber=38, createdTime=2024-05-09, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=03a3825081b6, moduleTitle=【Blood】ZUMA-7研究探索性分析，代谢肿瘤体积影响患者结局, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=03a3825081b6)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2200417, encodeId=d13c220041e42, content=<a href='/topic/show?id=247743555b6' target=_blank style='color:#2F92EE;'>#大B细胞淋巴瘤#</a> <a href='/topic/show?id=031811380ed4' target=_blank style='color:#2F92EE;'>#伴IRF4重排#</a>, objectTitle=【衡道丨病例】一文详解！伴IRF4重排的大B细胞淋巴瘤如何诊断？, objectType=article, longId=822301, objectId=a408822301ae, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221109/1668016274166_4754896.png, objectUrl=/article/show_article.do?id=a408822301ae, replyNumber=0, likeNumber=38, createdTime=2024-04-25, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=a408822301ae, moduleTitle=【衡道丨病例】一文详解！伴IRF4重排的大B细胞淋巴瘤如何诊断？, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=a408822301ae)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2195720, encodeId=53522195e20fb, content=<a href='/topic/show?id=247743555b6' target=_blank style='color:#2F92EE;'>#大B细胞淋巴瘤#</a> <a href='/topic/show?id=142f5429388' target=_blank style='color:#2F92EE;'>#扁桃体#</a> <a href='/topic/show?id=71a91128139f' target=_blank style='color:#2F92EE;'>#IRF4重排#</a>, objectTitle=病例分享 | 扁桃体伴IRF4重排的大B细胞淋巴瘤一例, objectType=article, longId=816647, objectId=17d981664e8f, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/doctor-in-his-practice-with-a-digital-tablet-UWZKVBN.jpg, objectUrl=/article/show_article.do?id=17d981664e8f, replyNumber=0, likeNumber=39, createdTime=2024-03-27, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=17d981664e8f, moduleTitle=病例分享 | 扁桃体伴IRF4重排的大B细胞淋巴瘤一例, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=17d981664e8f)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2194986, encodeId=06982194986dc, content=<a href='/topic/show?id=4e2640e283' target=_blank style='color:#2F92EE;'>#CAR-T细胞#</a> <a href='/topic/show?id=247743555b6' target=_blank style='color:#2F92EE;'>#大B细胞淋巴瘤#</a> <a href='/topic/show?id=ea112303079' target=_blank style='color:#2F92EE;'>#临床试验#</a>, objectTitle=Blood：CAR-T细胞产品liso-cel可增加复发性大B细胞淋巴瘤患者的生存率, objectType=article, longId=817842, objectId=f28181e8426a, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/bioon-com/20240323/1711206526562_2185383.png, objectUrl=/article/show_article.do?id=f28181e8426a, replyNumber=0, likeNumber=52, createdTime=2024-03-24, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=0, avatar=, status=0, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=null, followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2193690, encodeId=b3f22193690f1, content=<a href='/topic/show?id=247743555b6' target=_blank style='color:#2F92EE;'>#大B细胞淋巴瘤#</a> <a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a> <a href='/topic/show?id=4fa110931ac' target=_blank style='color:#2F92EE;'>#liso-cel#</a>, objectTitle=Clin Cancer Res：FDA批准liso-cel用于大B细胞淋巴瘤二线治疗的相关临床试验, objectType=article, longId=817252, objectId=5e1a81e252e0, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240316/1710562902043_6145188.jpg, objectUrl=/article/show_article.do?id=5e1a81e252e0, replyNumber=0, likeNumber=46, createdTime=2024-03-17, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=5e1a81e252e0, moduleTitle=Clin Cancer Res：FDA批准liso-cel用于大B细胞淋巴瘤二线治疗的相关临床试验, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=5e1a81e252e0)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2183529, encodeId=fb83218352955, content=<a href='/topic/show?id=c14d5638971' target=_blank style='color:#2F92EE;'>#指南#</a> <a href='/topic/show?id=247743555b6' target=_blank style='color:#2F92EE;'>#大B细胞淋巴瘤#</a>, objectTitle=【BJH】新诊断大B细胞淋巴瘤的治疗：英国血液学会指南, objectType=article, longId=810590, objectId=0b49810590eb, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/doctor-in-his-practice-with-a-digital-tablet-UWZKVBN.jpg, objectUrl=/article/show_article.do?id=0b49810590eb, replyNumber=0, likeNumber=59, createdTime=2024-01-23, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=0b49810590eb, moduleTitle=【BJH】新诊断大B细胞淋巴瘤的治疗：英国血液学会指南, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=0b49810590eb)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2182987, encodeId=8f11218298eaf, content=<a href='/topic/show?id=f0838291817' target=_blank style='color:#2F92EE;'>#肿瘤微环境#</a> <a href='/topic/show?id=247743555b6' target=_blank style='color:#2F92EE;'>#大B细胞淋巴瘤#</a> <a href='/topic/show?id=141d40627a' target=_blank style='color:#2F92EE;'>#CAR-T#</a>, objectTitle=【Nat Med】肿瘤微环境影响CAR-T或移植治疗LBCL的疗效, objectType=article, longId=810326, objectId=39f981032626, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/hospital-staff-doctor-review-PTX6YZP.jpg, objectUrl=/article/show_article.do?id=39f981032626, replyNumber=0, likeNumber=63, createdTime=2024-01-21, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=39f981032626, moduleTitle=【Nat Med】肿瘤微环境影响CAR-T或移植治疗LBCL的疗效, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=39f981032626)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2182994, encodeId=0a2b21829949c, content=<a href='/topic/show?id=247743555b6' target=_blank style='color:#2F92EE;'>#大B细胞淋巴瘤#</a> 在二线大 B 细胞淋巴瘤（LBCL）患者中开展的 III 期 ZUMA-7 研究证明，抗CD19 CAR-T 细胞治疗 (axicabtagene ciloleucel axi-cel]) 优效于标准治疗（SOC；挽救性化疗后进行造血移植）。然而研究证明，仍有相当数量的患者对CAR-T细胞疗法表现出原发性耐药(无应答)或继发性耐药(初始缓解后复发)，因此需要对与治疗耐药相关的潜在生物标志物进行进一步研究。, objectTitle=大B细胞淋巴瘤, objectType=topic, longId=43555, objectId=null, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=null, replyNumber=0, likeNumber=51, createdTime=2024-01-21, rootId=0, userName=yangchou, userId=88b489038, projectId=1, avatar=, status=1, hasArticle=0, attachment=null, ipAttribution=浙江省, moduleDTOList=null, followStatus=false, userIsMember=false, type=1, lengthMark=1), GetTopicListResponse(id=2174066, encodeId=1e7821e4066fa, content=<a href='/topic/show?id=247743555b6' target=_blank style='color:#2F92EE;'>#大B细胞淋巴瘤#</a> <a href='/topic/show?id=5b4640e04a' target=_blank style='color:#2F92EE;'>#CAR-T疗法#</a>, objectTitle=【Lancet Haematol】综述：CAR T作为LBCL二线治疗的几个关键问题, objectType=article, longId=804024, objectId=7767804024c6, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/patient-meeting-a-doctor-PAYSRMZ.jpg, objectUrl=/article/show_article.do?id=7767804024c6, replyNumber=0, likeNumber=177, createdTime=2023-12-10, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=7767804024c6, moduleTitle=【Lancet Haematol】综述：CAR T作为LBCL二线治疗的几个关键问题, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=7767804024c6)], followStatus=false, userIsMember=false, type=null, lengthMark=0)] 梅斯话题小助手

大B细胞淋巴瘤

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#大B细胞淋巴瘤# #CAR-T细胞治疗# #CD22#

柳叶刀发表CD22 CAR-T治疗CAR19失败的LBCL的I期研究，新的希望即将来临？

2024-07-23发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#苯达莫司汀# #大B细胞淋巴瘤# #R/R LBCL#

【Hemasphere】苯达莫司汀作为R/R LBCL CAR-T桥接治疗安全有效

2024-07-10发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#大B细胞淋巴瘤# #CAR-T# #LBCL#

CAR-T治疗后进展LBCL患者的后续治疗及结局

2024-07-02发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#大B细胞淋巴瘤# #代谢肿瘤体积#

【Blood】ZUMA-7研究探索性分析，代谢肿瘤体积可预测结局

2024-06-26发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#大B细胞淋巴瘤# #CAR-T#

【AJH】CD19 CAR-T治疗226例高龄RR LBCL患者安全有效

2024-06-15发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#大B细胞淋巴瘤# #CAR-T#

【Hemasphere】387例LBCL患者CAR-T治疗进展后的治疗及结局

2024-06-06发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#二线治疗# #大B细胞淋巴瘤# #LBCL#

【BJH】axi-cel二线治疗早期复发或原发难治LBCL的真实世界经验

2024-06-05发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#大B细胞淋巴瘤# #格菲妥单抗#

【Blood Adv】格菲妥单抗治疗DLBCL中≥2级CRS的预测模型

2024-06-01发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#大B细胞淋巴瘤# #CAR-T# #LBCL#

Leukemia：完全缓解的LBCL患者接受CAR-T细胞治疗：一项CIBMTR分析

2024-05-21发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#大B细胞淋巴瘤# #LBCL#

【Blood Adv】前瞻性研究明确定义原发难治性大B细胞淋巴瘤的概念

2024-05-12发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#DLBCL# #大B细胞淋巴瘤# #免疫豁免#

blood综述：免疫豁免部位的原发性大B细胞淋巴瘤

2024-05-10发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#大B细胞淋巴瘤# #代谢肿瘤体积# #LBCL#

【Blood】ZUMA-7研究探索性分析，代谢肿瘤体积影响患者结局

2024-05-09发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#大B细胞淋巴瘤# #伴IRF4重排#

【衡道丨病例】一文详解！伴IRF4重排的大B细胞淋巴瘤如何诊断？

2024-04-25发表于陕西省

梅斯管理员 (审核中...)

前往app查看评论内容

#大B细胞淋巴瘤# #扁桃体# #IRF4重排#

病例分享 | 扁桃体伴IRF4重排的大B细胞淋巴瘤一例

2024-03-27发表于陕西省

梅斯管理员 (审核中...)

前往app查看评论内容

#CAR-T细胞# #大B细胞淋巴瘤# #临床试验#

2024-03-24发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#大B细胞淋巴瘤# #二线治疗# #liso-cel#

Clin Cancer Res：FDA批准liso-cel用于大B细胞淋巴瘤二线治疗的相关临床试验

2024-03-17发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#指南# #大B细胞淋巴瘤#

【BJH】新诊断大B细胞淋巴瘤的治疗：英国血液学会指南

2024-01-23发表于陕西省

梅斯管理员 (审核中...)

前往app查看评论内容

#肿瘤微环境# #大B细胞淋巴瘤# #CAR-T#

【Nat Med】肿瘤微环境影响CAR-T或移植治疗LBCL的疗效

2024-01-21发表于陕西省

yangchou (审核中...)

前往app查看评论内容

全文收起 #大B细胞淋巴瘤# 在二线大 B 细胞淋巴瘤（LBCL）患者中开展的 III 期 ZUMA-7 研究证明，抗CD19 CAR-T 细胞治疗 (axicabtagene ciloleucel axi-cel]) 优效于标准治疗（SOC；挽救性化疗后进行造血移植）。然而研究证明，仍有相当数量的患者对CAR-T细胞疗法表现出原发性耐药(无应答)或继发性耐药(初始缓解后复发)，因此需要对与治疗耐药相关的潜在生物标志物进行进一步研究。

2024-01-21发表于浙江省

梅斯管理员 (审核中...)

前往app查看评论内容

#大B细胞淋巴瘤# #CAR-T疗法#

【Lancet Haematol】综述：CAR T作为LBCL二线治疗的几个关键问题

2023-12-10发表于上海

科室
- - 订阅+
  - 更多科室
工具
服务